BBIOBridgeBio Pharma, Inc.

$65.35+25% 1Y

Is the price fair?

What BBIO's price assumes

BridgeBio Pharma, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 19.1× revenue.

19.1

Price / sales · no P/E: the last twelve months did not end in a profit

EV / sales
21.9

EV / sales

Details›
EV / EBIToperating margin −70%: the multiple describes the denominator
not meaningful
EV / salestoday's price, trailing year to Jun 30, 2026
21.9
Market capitalisation
$13.6B

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Most shorted stocks